Madrigal Pharmaceuticals Analyst Price Targets

Madrigal Pharmaceuticals Inc

MDGLNASDAQ

Trade with Public

$447.09

-2.65-0.59%

Dern. MÀJ: Oct 19, 4:25 PM

$447.09

-2.65-0.59%

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

Madrigal Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Madrigal Pharmaceuticals (MDGL).

Price Target Range — 12 Quarters

Analyst Consensus — 18 Analysts

2S.Buy

15Buy

1Hold

Consensus RatingBuy# Analysts18Avg. Consensus PT$625Upside to Avg. PT+39.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Reinstates	Buy	$704
Sep 23, 2026	Citigroup	Eric Joseph	Initiate	Buy	$725
Aug 4, 2026	Wolfe Research	Andy Chen	Upgrade	Peer Perform→Outperform	$605
Aug 3, 2026	Barclays	Eliana Merle	PT Cut	Overweight	$964→$962
Jul 29, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$578→$587
Jul 27, 2026	Wells Fargo	Sadia Rahman	Initiate	Overweight	$685
Jun 11, 2026	B of A Securities	Alexandria Hammond	PT Cut	Neutral	$550→$542
May 13, 2026	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$640→$709
May 7, 2026	Canaccord Genuity	Edward Nash	PT Cut	Buy	$587→$578
May 7, 2026	Evercore ISI Group	Liisa Bayko	PT Cut	Outperform	$652→$649
May 6, 2026	HC Wainwright & Co.	Andrew S. Fein	Maintained	Buy	$620
Feb 20, 2026	B of A Securities	Alexandria Hammond	PT Cut	Neutral	$570→$529
Jan 28, 2026	Barclays	Eliana Merle	Initiate	Overweight	$964
Jan 20, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$527→$745
Dec 19, 2025	Piper Sandler	Yasmeen Rahimi	PT Raise	Overweight	$540→$900
Dec 11, 2025	B. Riley Securities	William Woods	PT Raise	Buy	$560→$670
Nov 21, 2025	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$568→$620
Nov 20, 2025	Oppenheimer	Jay Olson	PT Raise	Outperform	$600→$650
Nov 19, 2025	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$580→$640
Nov 13, 2025	Canaccord Genuity	Edward Nash	PT Raise	Buy	$526→$587

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Goldman Sachs Reinstates Buy on Madrigal Pharmaceuticals, Announces $704 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and announces $704 price target.

Benzinga Newsdesk

PRO
Citigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $725

Citigroup analyst Eric Joseph initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy rating and announces Price Target of $725.

Benzinga Newsdesk

This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Analysts upgraded Replimune, Madrigal, BBB Foods, Palantir, and Fomento Economico. See other opinions and price targets for these stocks.

Avi Kapoor

PRO
Wolfe Research Upgrades Madrigal Pharmaceuticals to Outperform, Announces $605 Price Target

Wolfe Research analyst Andy Chen upgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) from Peer Perform to Outperform and announces $605 price target.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Madrigal Pharmaceuticals, Lowers Price Target to $962

Barclays analyst Eliana Merle maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight and lowers the price target from $964 to $962.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587

Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $578 to $587.

Benzinga Newsdesk

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Goldman Sachs Reinstates Buy on Madrigal Pharmaceuticals, Announces $704 Price Target

PRO
Citigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $725

This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

PRO
Wolfe Research Upgrades Madrigal Pharmaceuticals to Outperform, Announces $605 Price Target

PRO
Barclays Maintains Overweight on Madrigal Pharmaceuticals, Lowers Price Target to $962

PRO
Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Madrigal Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Goldman Sachs Reinstates Buy on Madrigal Pharmaceuticals, Announces $704 Price Target

PRO
Citigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $725

This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

PRO
Wolfe Research Upgrades Madrigal Pharmaceuticals to Outperform, Announces $605 Price Target

PRO
Barclays Maintains Overweight on Madrigal Pharmaceuticals, Lowers Price Target to $962

PRO
Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587

People Also Watch

People Also Watch

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGoldman Sachs Reinstates Buy on Madrigal Pharmaceuticals, Announces $704 Price Target

PROCitigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $725

This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

PROWolfe Research Upgrades Madrigal Pharmaceuticals to Outperform, Announces $605 Price Target

PROBarclays Maintains Overweight on Madrigal Pharmaceuticals, Lowers Price Target to $962

PROCanaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Madrigal Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGoldman Sachs Reinstates Buy on Madrigal Pharmaceuticals, Announces $704 Price Target

PROCitigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $725

This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

PROWolfe Research Upgrades Madrigal Pharmaceuticals to Outperform, Announces $605 Price Target

PROBarclays Maintains Overweight on Madrigal Pharmaceuticals, Lowers Price Target to $962

PROCanaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587

People Also Watch

People Also Watch

PRO
Goldman Sachs Reinstates Buy on Madrigal Pharmaceuticals, Announces $704 Price Target

PRO
Citigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $725

PRO
Wolfe Research Upgrades Madrigal Pharmaceuticals to Outperform, Announces $605 Price Target

PRO
Barclays Maintains Overweight on Madrigal Pharmaceuticals, Lowers Price Target to $962

PRO
Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587

PRO
Goldman Sachs Reinstates Buy on Madrigal Pharmaceuticals, Announces $704 Price Target

PRO
Citigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $725

PRO
Wolfe Research Upgrades Madrigal Pharmaceuticals to Outperform, Announces $605 Price Target

PRO
Barclays Maintains Overweight on Madrigal Pharmaceuticals, Lowers Price Target to $962

PRO
Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587